跳至主要内容
临床试验/CTRI/2024/09/074423
CTRI/2024/09/074423已完成Phase 3 4

To Study the Efficacy and Safety of Intravenous Amisulpride against Ondansetron in Post-Surgical Patients undergoing general Anaesthesia to Prevent Post Operative Nausea Vomiting (PONV)- An Interventional, Randomised, Controlled Prospective Study

Sumandeep Vidyapeeth Deemed to be Univeersity1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年10月7日最近更新:

试验速览

阶段
Phase 3 4
状态
已完成
发起方
入组人数
100
试验地点
1
主要终点
Complete response of medicine that is no episodes of emesis and no use of rescue medication in first 24 hours after wound closure or PONV.

研究概览

简要总结

Traditionally ondansetron is used as an antiemetic to prevent post-operative nausea and vomiting (PONV), which is a 5HT3 Receptor blocker. Amisulpride is a dopamine receptor antagonist with less incidence of extrapyramidal symptoms in a safe dose range from 50- 1200 mg. Now it is recently available as (Sultran 5mg/ 2ml preparation in India) an antiemetic drug to prevent post-operative nausea and vomiting. So we have to study the efficacy and safety of intravenous amisulpride against ondansetron in post-surgical patients undergoing general anaesthesia to prevent post-operative nausea and vomiting (PONV).

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant Blinded

入排标准

年龄范围
18.00 Year(s) 至 65.00 Year(s)(—)
性别
All

入选标准

  • • Surgery to last at least 1 hour • Overnight stay • General anaesthesia • ASA I&II • At least one of the following Apfel et al’s risk factors for PONV: ï‚§ Female sex ï‚§ Non-smoking status ï‚§ A prior history of PONV or motion sickness ï‚§ Being expected to receive postoperative opioid analgesia.

排除标准

  • If any antihistaminic, continuous infusion of propofol or dexmedetomidine, steroids, any antiemetics is used 24 hours prior or post-surgery then the case will be not selected for the study.

结局指标

主要结局

Complete response of medicine that is no episodes of emesis and no use of rescue medication in first 24 hours after wound closure or PONV.

时间窗: 0,2,6,8,12,24,48 hours

次要结局

  • To observe the incidence of nausea, emesis, use of rescue medication any adverse event.(0,2,6,8,12,24,48 hours)

研究者

发起方
Sumandeep Vidyapeeth Deemed to be Univeersity
申办方类型
Private medical college
责任方
Principal Investigator
主要研究者

Dr Tejash H Sharma

Dept. of Anaesthesiology, SBKS MIRC

研究点 (1)

Loading locations...

相似试验